Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
about
Assessment of bone tissue mineralization by conventional x-ray microcomputed tomography: comparison with synchrotron radiation microcomputed tomography and ash measurements.Evaluating bone quality in patients with chronic kidney disease.Effect of Traditional Chinese Medicine Product, QiangGuYin, on Bone Mineral Density and Bone Turnover in Chinese Postmenopausal Osteoporosis.The influence of disuse on bone microstructure and mechanics assessed by HR-pQCT.Testing two predictions for fracture load using computer models of trabecular bone.Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged ratsEffects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.Variations in morphological and biomechanical indices at the distal radius in subjects with identical BMD.A1330V polymorphism of the low-density lipoprotein receptor-related protein 5 gene and bone mineral density in Japanese male workersBone quality: from bench to bedside: opening editorial commentOsthole stimulates osteoblast differentiation and bone formation by activation of beta-catenin-BMP signaling.A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.Diet, nutrition and the prevention of osteoporosis.Accuracy of volumetric bone mineral density measurement in high-resolution peripheral quantitative computed tomography.Bone microarchitecture as an important determinant of bone strength.Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.A biomechanical perspective on bone quality.Examining the relationship between bone mineral density and fracture risk reduction during pharmacologic treatment of osteoporosis.Vascular calcification and renal osteodystrophy relationship in chronic kidney disease.Osteoporosis: how should it be treated?Examining the Relationships Between Bone Tissue Composition, Compositional Heterogeneity, and Fragility Fracture: A Matched Case-Controlled FTIRI Study.Recent advances in the noninvasive diagnosis of renal osteodystrophy.Prevention, screening, and management of osteoporosis: an overview of the current strategies.Bone quality and osteoporosis therapy.Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition).The management of pain from collapse of osteoporotic vertebrae with continuous intrathecal morphine infusion.Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis.Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial.Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis.Genetic determinants of osteoporosis susceptibility in a female Ashkenazi Jewish population.Optimal decision criterion for detecting change in bone mineral density during serial monitoring: a Bayesian approach.
P2860
Q33359455-F8301A91-8B18-44F6-A64F-55409C94308BQ33602332-9E2B2C0B-3E15-4054-A49D-AC781A647967Q33635025-EF4F1B07-F6D4-4454-9620-436B0BE4394AQ33699245-BE12F9C3-114E-4656-80A4-21332D31D07AQ34350853-95E83846-8FBC-4593-8A61-E65E4C232886Q34411999-B2ECED22-4707-46BB-A186-10DBBC220E41Q34439029-53A956A1-AE3C-4C32-80A0-A83966E9C527Q34482348-605A8F70-8B5B-499E-AE73-D43621EF309FQ34619205-5F9C3613-301B-4778-A592-774B38B80816Q35078850-D53D8A8D-E2C2-4CFE-B9C0-3597BA8DCDA3Q35155501-DC64A079-AE27-4F15-9C7F-90673151936CQ35229815-98BDA2AA-C02B-401B-A787-323D5C53E2B7Q35670622-3C2A09BA-135F-4B09-94A6-84DCD65192F6Q35680719-B2452CCD-4F65-43F7-9F9B-195F75AE2EA6Q35724866-4AD48FE5-CB0B-4070-8F7B-B47F8F1DDB0BQ35747404-62D75C1B-B568-46C8-8CDF-71C1E7A79FBFQ35809562-2176D436-96AB-4E8F-8448-683FFCE27A58Q36408738-1F448099-B601-4C17-BE50-CC2ACF501E5DQ36554786-6F9C10C7-4753-4258-9790-F5C73F0501B5Q36583646-B4C2551D-B8E9-4A52-9EC1-04FCC26E4AAEQ36889362-E8B048E8-8EE7-479E-84C8-31103CEF3740Q37248630-1653B676-007E-4708-A328-330567D903B9Q37566044-16F9BE81-0073-4A79-9EAB-0FD69E60F8A1Q37756589-82BE3BA5-666C-42CB-98A7-06BEC083BC54Q38059153-461A7965-EADC-4D6D-96AD-8C074AC030E7Q39337548-D9DDE27C-59BB-412B-A4B7-9C5E843D1AE9Q40551220-1035CDB1-5428-46B8-B3A8-0BBB412CF4A0Q43506698-B68BBBD9-84FE-4FB5-A3D3-85F727B45486Q44429736-B5502EFE-6DD7-4B08-9AA6-3FE94BE22012Q46537462-86B3BF6C-9F2C-457B-8355-AFD31C925676Q51888066-DDE0593C-F56F-459E-80FD-A6083460BFCE
P2860
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
@ast
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
@en
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
@nl
type
label
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
@ast
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
@en
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
@nl
prefLabel
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
@ast
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
@en
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
@nl
P2093
P2860
P1476
Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.
@en
P2093
Bone Quality Discussion Group
C H Chesnut
P2860
P304
P356
10.1359/JBMR.2001.16.12.2163
P577
2001-12-01T00:00:00Z